SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-18-066648
Filing Date
2018-11-07
Accepted
2018-11-07 16:07:21
Documents
59
Period of Report
2018-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q a18-19037_110q.htm 10-Q 807432
2 EX-31.1 a18-19037_1ex31d1.htm EX-31.1 12122
3 EX-31.2 a18-19037_1ex31d2.htm EX-31.2 12111
4 EX-32.1 a18-19037_1ex32d1.htm EX-32.1 7895
  Complete submission text file 0001104659-18-066648.txt   4549993

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT cldx-20180930.xml EX-101.INS 1089810
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cldx-20180930.xsd EX-101.SCH 31786
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cldx-20180930_cal.xml EX-101.CAL 48669
8 XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT cldx-20180930_lab.xml EX-101.LAB 348059
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cldx-20180930_pre.xml EX-101.PRE 250653
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cldx-20180930_def.xml EX-101.DEF 127658
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-15006 | Film No.: 181166348
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Assistant Director 1